Lava fires up a $700m cancer licensing deal with Seagen
pharmaphorum
SEPTEMBER 27, 2022
While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. The biotech said earlier it planned to seek FDA approval to start clinical trials towards the end of 2022.
Let's personalize your content